---
title: "Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma"
date: "2025-09-19T04:00:00.000Z"
publishedDate: "19 septembre 2025"
summary: "Conditions : Recurrent Multiple Myeloma; Refractory Multiple Myeloma; Triple-Class Refractory Multiple Myeloma Interventions : Biological: Linvoseltamab; Procedure: Bone Marrow Aspiration; Procedure: Bone Marrow Biopsy; Procedure: Computed Tomography; Procedure: Positron Emission Tomography; Procedure: Biospecimen Collection Sponsors : Fred Hutchinson Cancer Center; Regeneron Pharmaceuticals Not yet recruiting"
importance: ""
sourceUrl: "https://clinicaltrials.gov/study/NCT07181941?term=interventional+radiology&aggFilters=status%3A"
tags: ["France", "Actualité", "ClinicalTrials.gov — ta recherche"]
permalink: "/papers/2025-09-19-response-based-dose-reduction-of-linvoseltamab-in-the-treatment-of-relapsed-refractory-or-triple-class-relapsedrefractory-multiple-myeloma"
imageUrl: ""
imageCredit: ""
---

## L’essentiel

Conditions : Recurrent Multiple Myeloma; Refractory Multiple Myeloma; Triple-Class Refractory Multiple Myeloma Interventions : Biological: Linvoseltamab; Procedure: Bone Marrow Aspiration; Procedure: Bone Marrow Biopsy; Procedure: Computed Tomography; Procedure: Positron Emission Tomography; Procedure: Biospecimen Collection Sponsors : Fred Hutchinson Cancer Center; Regeneron Pharmaceuticals Not yet recruiting

## Lien source

https://clinicaltrials.gov/study/NCT07181941?term=interventional+radiology&aggFilters=status%3A
